Affiliation:
1. Department of Pharmacology, Columbia Institute of Pharmacy, Raipur, Chhattisgarh, 493111, India
Abstract
Abstract:
An important sensation that warns of potential harm to a specific area of the body is
pain. The prevalence of pain-related conditions globally is a significant and growing public health
issue. Chronic pain affects an estimated 1.5 billion people worldwide, with prevalence rates varying
by region and demographic factors. Along with diabetes, cardiovascular disease, and cancer,
pain is among the most frequent medical diseases. Opioid analgesics are the mainstay of current
pain therapies, which are ineffective. Opioid addiction and its potentially fatal side effects necessitate
novel treatment strategies. Nanotechnology offers potential advantages in pain management
by enabling targeted drug delivery, which can enhance the efficacy and reduce the side effects of
analgesic medications. Additionally, nanoparticles can be designed to release drugs in a controlled
manner, improving pain relief duration and consistency. This approach also allows for the delivery
of therapeutics across biological barriers, potentially enhancing treatment outcomes for chronic
pain conditions. Nanomedicine enables sensitive and focused treatments with fewer side effects
than existing clinical pain medicines; it is worth exploring as a potential solution to these
problems. Furthermore, medication delivery systems that use nanomaterials are being used to treat
pain. Whether it's the distribution of a single medication or a combination of therapies, this review
seeks to summarise the ways in which drug delivery systems based on nanomaterials can be
utilised to successfully treat and alleviate pain. For the purpose of writing this paper, we consulted
several online libraries, including Pubmed, Science Direct, Pubmed Prime, and the Cochrane Library,
to gather fresh and up-to-date material. This overview delves into the ins and outs of pain's
pathophysiology, the present state of pain treatment, potential new pain treatment targets, and the
various initiatives that have been launched and are still in the works to address pain with nanotechnology.
Recent developments in nanomaterials-based scavenging, gene therapy for pain aetiology,
and nanoparticle-based medicine delivery for side effect reduction are highlighted. Analgesics
have been further covered in our discussion on FDA-approved pharmaceuticals and clinical advancements.
Publisher
Bentham Science Publishers Ltd.